Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Diversity-Oriented Synthesis as a Strategy for Fragment Evolution against GSK3β.

Wang Y, Wach JY, Sheehan P, Zhong C, Zhan C, Harris R, Almo SC, Bishop J, Haggarty SJ, Ramek A, Berry KN, O'Herin C, Koehler AN, Hung AW, Young DW.

ACS Med Chem Lett. 2016 Jul 14;7(9):852-6. doi: 10.1021/acsmedchemlett.6b00230. eCollection 2016 Sep 8.

2.

Recent Applications of Diversity-Oriented Synthesis Toward Novel, 3-Dimensional Fragment Collections.

Kidd SL, Osberger TJ, Mateu N, Sore HF, Spring DR.

Front Chem. 2018 Oct 16;6:460. doi: 10.3389/fchem.2018.00460. eCollection 2018. Review.

3.

Novel approach of fragment-based lead discovery applied to renin inhibitors.

Tawada M, Suzuki S, Imaeda Y, Oki H, Snell G, Behnke CA, Kondo M, Tarui N, Tanaka T, Kuroita T, Tomimoto M.

Bioorg Med Chem. 2016 Nov 15;24(22):6066-6074. doi: 10.1016/j.bmc.2016.09.065. Epub 2016 Sep 28.

PMID:
27720325
4.

Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities.

Huang B, Kang D, Zhan P, Liu X.

Expert Opin Drug Discov. 2015 Dec;10(12):1271-81. doi: 10.1517/17460441.2015.1083007. Epub 2015 Sep 15. Review.

PMID:
26372893
5.

Route to three-dimensional fragments using diversity-oriented synthesis.

Hung AW, Ramek A, Wang Y, Kaya T, Wilson JA, Clemons PA, Young DW.

Proc Natl Acad Sci U S A. 2011 Apr 26;108(17):6799-804. doi: 10.1073/pnas.1015271108. Epub 2011 Apr 11.

6.

Lead generation and examples opinion regarding how to follow up hits.

Orita M, Ohno K, Warizaya M, Amano Y, Niimi T.

Methods Enzymol. 2011;493:383-419. doi: 10.1016/B978-0-12-381274-2.00015-7.

PMID:
21371599
7.

Advances in fragment-based drug discovery platforms.

Orita M, Warizaya M, Amano Y, Ohno K, Niimi T.

Expert Opin Drug Discov. 2009 Nov;4(11):1125-44. doi: 10.1517/17460440903317580.

PMID:
23480433
8.

How Size Matters: Diversity for Fragment Library Design.

Shi Y, von Itzstein M.

Molecules. 2019 Aug 5;24(15). pii: E2838. doi: 10.3390/molecules24152838.

9.

Diversity-oriented synthesis of bicyclic fragments containing privileged azines.

Luise N, Wyatt PG.

Bioorg Med Chem Lett. 2019 Jan 15;29(2):248-251. doi: 10.1016/j.bmcl.2018.11.046. Epub 2018 Nov 24.

10.

From Protein Structure to Small-Molecules: Recent Advances and Applications to Fragment-Based Drug Discovery.

Ferreira LG, Andricopulo AD.

Curr Top Med Chem. 2017;17(20):2260-2270. doi: 10.2174/1568026617666170224113437. Review.

PMID:
28240184
11.

Assessment of Dengue virus helicase and methyltransferase as targets for fragment-based drug discovery.

Coutard B, Decroly E, Li C, Sharff A, Lescar J, Bricogne G, Barral K.

Antiviral Res. 2014 Jun;106:61-70. doi: 10.1016/j.antiviral.2014.03.013. Epub 2014 Apr 1.

PMID:
24704437
12.

Two 'Golden Ratio' indices in fragment-based drug discovery.

Orita M, Ohno K, Niimi T.

Drug Discov Today. 2009 Mar;14(5-6):321-8. doi: 10.1016/j.drudis.2008.10.006. Epub 2008 Dec 10. Review.

PMID:
19028598
13.

Effective progression of nuclear magnetic resonance-detected fragment hits.

Eaton HL, Wyss DF.

Methods Enzymol. 2011;493:447-68. doi: 10.1016/B978-0-12-381274-2.00017-0.

PMID:
21371601
14.

In silico fragment-based drug discovery: setup and validation of a fragment-to-lead computational protocol using S4MPLE.

Hoffer L, Renaud JP, Horvath D.

J Chem Inf Model. 2013 Apr 22;53(4):836-51. doi: 10.1021/ci4000163. Epub 2013 Apr 11.

PMID:
23537132
15.

Fragment informatics and computational fragment-based drug design: an overview and update.

Sheng C, Zhang W.

Med Res Rev. 2013 May;33(3):554-98. doi: 10.1002/med.21255. Epub 2012 Mar 19. Review.

PMID:
22430881
16.

Fragment-assisted hit investigation involving integrated HTS and fragment screening: Application to the identification of phosphodiesterase 10A (PDE10A) inhibitors.

Varnes JG, Geschwindner S, Holmquist CR, Forst J, Wang X, Dekker N, Scott CW, Tian G, Wood MW, Albert JS.

Bioorg Med Chem Lett. 2016 Jan 1;26(1):197-202. doi: 10.1016/j.bmcl.2015.10.100. Epub 2015 Nov 11.

PMID:
26597534
17.

Fragment Linking and Optimization of Inhibitors of the Aspartic Protease Endothiapepsin: Fragment-Based Drug Design Facilitated by Dynamic Combinatorial Chemistry.

Mondal M, Radeva N, Fanlo-Virgós H, Otto S, Klebe G, Hirsch AK.

Angew Chem Int Ed Engl. 2016 Aug 1;55(32):9422-6. doi: 10.1002/anie.201603074. Epub 2016 Jul 12.

18.

Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of Malaria.

Heidebrecht RW Jr, Mulrooney C, Austin CP, Barker RH Jr, Beaudoin JA, Cheng KC, Comer E, Dandapani S, Dick J, Duvall JR, Ekland EH, Fidock DA, Fitzgerald ME, Foley M, Guha R, Hinkson P, Kramer M, Lukens AK, Masi D, Marcaurelle LA, Su XZ, Thomas CJ, Weïwer M, Wiegand RC, Wirth D, Xia M, Yuan J, Zhao J, Palmer M, Munoz B, Schreiber S.

ACS Med Chem Lett. 2012 Feb 9;3(2):112-117. Epub 2011 Dec 22.

19.

Combining NMR and X-ray crystallography in fragment-based drug discovery: discovery of highly potent and selective BACE-1 inhibitors.

Wyss DF, Wang YS, Eaton HL, Strickland C, Voigt JH, Zhu Z, Stamford AW.

Top Curr Chem. 2012;317:83-114. doi: 10.1007/128_2011_183. Review.

PMID:
21647837
20.

The multiple roles of computational chemistry in fragment-based drug design.

Law R, Barker O, Barker JJ, Hesterkamp T, Godemann R, Andersen O, Fryatt T, Courtney S, Hallett D, Whittaker M.

J Comput Aided Mol Des. 2009 Aug;23(8):459-73. doi: 10.1007/s10822-009-9284-1. Epub 2009 Jun 17.

PMID:
19533374

Supplemental Content

Support Center